Presentation (CTI)

OBJECTIVES: The German National Psoriasis Registry PsoBest gains long-term evidence on safety, effectiveness, and patient benefits of psoriasis treatment in routine care. The aim was to assess baseline treatment needs and evaluate treatment benefits at 3, 6, and 12 months cross-sectionally using the Patient-Benefit-Index (PBI) in patients treated with ixekizumab.
METHODS: The PsoBest dataset comprised 19,785 patients registered until 30-JUN-2024. All patients starting ixekizumab therapy at baseline were selected for descriptive and cross-sectional analysis at months 3, 6, and 12. PBI was calculated using the Patient-Needs-Questionnaire (PNQ) and the Patient-Benefit-Questionnaire (PBQ), each with 25 items. Before treatment, patients rated the importance of each treatment goal on a 5-point Likert-scale (0=not important, 4=very important). After treatment, the PBQ assessed goal achievement on a similar scale (0=not at all, 4=fully met). PBI is the weighted average of achieved benefits, with a score of ≥1 indicating patient relevant treatment benefit.
RESULTS: 670 patients initiated ixekizumab. Overall, the mean age was 48.1 years, 58.8% were male, 41.2% had psoriatic arthritis, and 56.0% had nail psoriasis. The median Psoriasis Area and Severity Index (PASI) was 13.1, and the median duration of the disease was 18.0 years. The most important patient needs rated as “quite or very important” were “be healed of all skin defects”, “regain control of the disease”, and “get better skin quickly” (96.8%, 96.8%, and 95.9%, respectively). Almost all PNQ items (24 of 25) achieved mean scores ≥3. At months 3, 6, and 12 median PASI was 1.2, 0.4, and 0.6; median PBI scores were 3.4, 3.7, and 3.7. High patient benefits (PBI ≥3) were achieved by 69.0%, 80.1%, and 75.4% of patients, respectively.
CONCLUSIONS: Patients receiving ixekizumab demonstrated considerable clinical improvements and meaningful benefits at each time point, despite high treatment needs at baseline indicating high disease burden.